soliqua solution for injection in a pre-filled pen 100unitsml + 50mcgml
sanofi-aventis singapore pte. ltd. - insulin glargine; lixisenatide - injection, solution - insulin glargine 100 units/ml; lixisenatide 50 μg/ml
ozempic
novo nordisk ltd., israel - semaglutide - solution for injection - semaglutide 1.34 mg / 1 ml - semaglutide - ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications• in addition to other medicinal products for the treatment of diabetes.
trulicity 1.5 mg 4 plumes precarregades 0.5 ml
trulicity 0.75 mg 4 plumes precarregades 0.5 ml
kexxtone capsule
elanco canada limited - monensin (monensin sodium) - capsule - 32.4g - monensin (monensin sodium) 32.4g - cattle
panto-denk 20
advance pharma gmbh - pantoprazole (pantoprazole sodium sesquihydrate) - tablets gastro-resistant - 20mg
panto-denk 40
advance pharma gmbh - pantoprazole (pantoprazole sodium sesquihydrate) - tablets gastro-resistant - 40mg
doxy-denk 100 tablets
artesan pharma gmbh & co. kg - doxycycline (doxycycline hyclate) - tablets - 100mg
tramadol denk 100mg/2ml solution for injection/infusion
solupharm pharmazeutische erzeugnisse gmbh - tramadol (tramadol hydrochloride) - solution for injection/infusion - 50mg/ml
saxenda
novo nordisk pharmaceuticals ltd - liraglutide 6 mg/ml; - solution for injection - 6 mg/ml - active: liraglutide 6 mg/ml excipient: dibasic sodium phosphate dihydrate hydrochloric acid phenol propylene glycol sodium hydroxide water for injection - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of · 30 kg/m2 or greater (obese) or · 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea. treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.